Guidelines on the diagnosis and management of the progressive ataxias

Silva R. de
J Greenfield
A Cook
H Bonney
J Vallortigara
et al. See next page for additional authors

Let us know how access to this document benefits you

General rights
All content in PEARL is protected by copyright law. Author manuscripts are made available in accordance with publisher policies. Please cite only the published version using the details provided on the item record or document. In the absence of an open licence (e.g. Creative Commons), permissions for further reuse of content should be sought from the publisher or author.

Take down policy
If you believe that this document breaches copyright please contact the library providing details, and we will remove access to the work immediately and investigate your claim.

Follow this and additional works at: https://pearl.plymouth.ac.uk/more-foh-research

Recommended Citation
de, S. R., Greenfield, J., Cook, A., Bonney, H., Vallortigara, J., Hunt, B., & Giunti, P. (2019) 'Guidelines on the diagnosis and management of the progressive ataxias', Orphanet Journal of Rare Diseases, 14(1).
Available at: 10.1186/s13023-019-1013-9
This Article is brought to you for free and open access by the Faculty of Health at PEARL. It has been accepted for inclusion in More Faculty of Health Research by an authorized administrator of PEARL. For more information, please contact openresearch@plymouth.ac.uk.
Guidelines on the diagnosis and management of the progressive ataxias

Rajith de Silva1, Julie Greenfield2, Arron Cook3, Harriet Bonney2, Julie Vallortigara2, Barry Hunt2 and Paola Giunti3*

Abstract

The progressive ataxias are a group of rare and complicated neurological disorders, knowledge of which is often poor among healthcare professionals (HCPs). The patient support group Ataxia UK, recognising the lack of awareness of this group of conditions, has developed medical guidelines for the diagnosis and management of ataxia. Although ataxia can be a symptom of many common conditions, the focus here is on the progressive ataxias, and include hereditary ataxia (e.g. spinocerebellar ataxia (SCA), Friedreich’s ataxia (FRDA)), idiopathic sporadic cerebellar ataxia, and specific neurodegenerative disorders in which ataxia is the dominant symptom (e.g. cerebellar variant of multiple systems atrophy (MSA-C)). Over 100 different disorders can lead to ataxia, so diagnosis can be challenging. Although there are no disease-modifying treatments for most of these entities, many aspects of the conditions are treatable, and their identification by HCPs is vital. The early diagnosis and management of the (currently) few reversible causes are also of paramount importance. More than 30 UK health professionals with experience in the field contributed to the guidelines, their input reflecting their respective clinical expertise in various aspects of ataxia diagnosis and management. They reviewed the published literature in their fields, and provided summaries on “best” practice, including the grading of evidence available for interventions, using the Guideline International Network (GIN) criteria, in the relevant sections.

A Guideline Development Group, consisting of ataxia specialist neurologists and representatives of Ataxia UK (including patients and carers), reviewed all sections, produced recommendations with levels of evidence, and discussed modifications (where necessary) with contributors until consensus was reached. Where no specific published data existed, recommendations were based on data related to similar conditions (e.g. multiple sclerosis) and/or expert opinion. The guidelines aim to assist HCPs when caring for patients with progressive ataxia, indicate evidence-based (where it exists) and best practice, and act overall as a useful resource for clinicians involved in managing ataxic patients. They do, however, also highlight the urgent need to develop effective disease-modifying treatments, and, given the large number of recommendations based on “good practice points”, emphasise the need for further research to provide evidence for effective symptomatic therapies. These guidelines are aimed predominantly at HCPs in secondary care (such as general neurologists, clinical geneticists, physiotherapists, speech and language therapists, occupational therapists, etc.) who provide care for individuals with progressive ataxia and their families, and not ataxia specialists. It is a useful, practical tool to forward to HCPs at the time referrals are made for on-going care, for example in the community.

* Correspondence: p.giunti@ucl.ac.uk
3Ataxia Centre, Department of Molecular Neurosciences, UCL Queen Square Institute of Neurology, Queen Square, London WC1N 3BG, UK
Full list of author information is available at the end of the article

© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Introduction

The progressive ataxias are a heterogenous group of (individually) rare neurological conditions. Epidemiological evidence is lacking, but recent estimates suggest that there are at least 10,000 adults and 500 children with progressive ataxia in the UK [1, 2]. Whereas incidence rates for the progressive ataxias collectively are not known, some specific conditions have been well characterised. For example, Friedreich’s ataxia (FRDA), the most common inherited ataxia, has an estimated incidence rate of 1:29,000 amongst Caucasians [3].

The word ataxia means ‘lack of coordination’, and these conditions typically present with unsteadiness and imbalance, clumsiness, and slurred speech. Gait and balance problems often progress to the point at which patients become wheelchair-bound, and, in general, the level of disability progresses at the cost of functional independence. Communication becomes progressively impaired as a result of speech disturbances. Various other symptoms are associated with specific ataxia conditions, including spasticity, tremor, sensory disturbance, auditory and visual impairment, bladder and bowel dysfunction, cardiac complications, musculoskeletal complications, and cognitive impairment.

These rare and complex conditions present a significant diagnostic challenge, and both patients and clinicians alike have reported inefficient and arduous journeys which often fail to establish a definitive cause [4]. Beyond diagnosis, understanding of management options amongst HCPs is lacking, and as such patients face enormous challenges in both understanding their illness and obtaining treatment. Despite the absence of disease-modifying treatments for most ataxias, many aspects of these disorders are treatable, and it is essential that the responsible HCPs know how best to manage these symptoms optimally. The aim of these guidelines is therefore to increase awareness of these conditions among non-specialists HCPs (mostly in secondary care, such as general neurologists, clinical geneticists, physiotherapists, speech and language therapists, occupational therapists, etc.), and to improve their diagnosis and management. Recently the guidelines were affirmed and considered ready for dissemination by the European Reference Network for Rare Neurological Diseases, highlighting their recognition internationally.

These guidelines focus on the progressive ataxias, and exclude disorders where ataxia is an epiphenomenon of another neurological condition. Specifically, the recommendations cover the inherited ataxias (e.g. FRDA, SCAs), idiopathic sporadic cerebellar ataxia and specific neurological conditions in which ataxia is the dominant symptom (e.g. MSA-C). Of note, these guidelines do not cover ataxia that results from vascular, inflammatory or neoplastic pathology. In addition, information about the extra-neurological features of Ataxia Telangiectasia are not included in these guidelines, but these are covered elsewhere [5].

Methods

The guidelines have been developed under the aegis of the patient support organisation, Ataxia UK, through extensive consultation with numerous UK neurologists, and other specialist physicians, surgeons, and therapists with experience in the diagnosis and management of ataxia. Contributors for each section were selected on account of their clinical expertise in aspects of ataxia diagnosis and management. More than 30 UK health professionals (please see Additional file 1: Table S1) contributed. They reviewed the available medical literature for their section using standard databases (e.g. PubMed, MEDLINE, Cochrane Database of Systematic Reviews, EMBASE and Scopus) and provided scientific evidence for the efficacy of different interventions. They graded the level of evidence following the Guideline International Network (GIN) protocol [6]. This included contributors critically reviewing the scientific evidence for the efficacy of interventions. For each paper, a judgement was made on the level of evidence (I to IV), any uncertainty was documented, and pertinent conclusions were drawn.

Earlier versions of the Ataxia UK guidelines (in 2007 and 2009) did not attempt to grade the quality of evidence supporting recommendations. In this iteration, data on the level of available evidence were used to allocate a grade to each recommendation, in accordance with criteria used internationally [7, 8]. Table 1 details the level of evidence and scheme for grading recommendations in these guidelines.

A Guideline Development Group consisting of neurologists with expertise in ataxia and representatives of Ataxia UK reviewed all the sections and discussed any changes with contributors consensually.

Results

The guidelines comprise 128 recommendations, grouped in four sections: on diagnosis and medical interventions, with two additional sections (available here in the Additional file 1) relating to in depth information about holistic/multi-disciplinary therapy and palliative care. Grading of the 128 recommendations were as follows: 6 graded B, 7 graded C, 10 graded D, and 105 graded as GPP. The full guidelines are available on the Ataxia UK website (https://www.ataxia.org.uk/Pages/Category/medical-guidelines).

Diagnosis

The ataxias can present in a variety of ways, so an accurate and comprehensive history, together with clinical examination and relevant investigations are essential for
Table 1 Evidence grading scheme for these guidelines

| Level of evidence [7] | Description |
|-----------------------|-------------|
| I                     | Evidence obtained from a systematic review of all relevant randomised controlled trials. |
| II                    | Evidence obtained from at least one randomised controlled trial. |
| III-a                 | Evidence obtained from one or more controlled trials, pseudo-randomised by alternate allocation, birth date or other planned method. |
| III-b                 | Evidence obtained from prospective or retrospective cohort studies with concurrent controls, case-control studies, or interrupted time-series with a control group. |
| III-c                 | Evidence obtained from cohort studies with historical controls, two or more single-arm studies, or interrupted time-series without a parallel control group. |
| IV                    | Evidence comprises opinions based on clinical experience, descriptive studies or reports by clinical bodies or committees. |

Grading of recommendations [8]

| Grade | Description |
|-------|-------------|
| A     | Body of evidence can be trusted to guide practice; includes one or more level I studies, or several at level II directly applicable to the target population, and demonstrating overall consistency of results. |
| B     | Body of evidence can be trusted to guide practice in most situations; includes one or two studies rated as level II or several level III studies, directly applicable to the target population, and demonstrating overall consistency of results. |
| C     | Body of evidence provides some support for recommendation(s) but care should be taken in its application; includes studies rated as level III-c, or level I or II with a moderate risk of bias, some inconsistency and applicable to target population with caveats. Population studied is not the target population, however, it would make sense clinically to apply this evidence to target population. |
| D     | Body of evidence is weak and recommendations must be applied with caution; includes level IV, or level I to IV studies with high risk of bias, inconsistent evidence and that are not applicable to target population. |

Good practice point: Recommended best practice based on clinical experience and expert opinion.

Table 2 Diagnostic investigations in adults

| Primary care | U&Es | Liver enzymes | Folate |
|--------------|------|---------------|--------|
| Creatinine   |      | y-GT          | Glucose|
| FBC          |      | TFT           | CXR    |
| ESR/CRP      |      | Vitamin B12   |        |
| Secondary care | Blood film | Lactate      | Anti-HuYo and other |
| (first line) | Caeruloplasmin/copper | Lipid-adjusted vitamin E and lipoproteins | paraneoplastic antibodies |
| Coeliac screen | Lumbar puncture (cells, protein, glucose, cytology, | Anti-GAD |
| Creatine kinase | oligoclonal bands, lactate, ferritin) | Anti-VGCC |
| Genetic tests for FRDA, SCA 1, 2, 3, 6, 7 (12, 17) and FXTAS | MRI brain and cervical spine | CT (chest, abdomen, pelvis) |
| Secondary care | Cholesterol | Muscle biopsy | 14–3-3 and other proteins in |
| (second line) | Plasma oxysterols | Ophthalmology/OCT | CSF (prion diseases) |
| Bile acids   |      | Peripheral nerve conduction studies | Remaining genetic tests (NGS) |
| Coenzyme Q10(ubiquinone) | Phytic acid | Total body PET scan | |
| Electroencephalography | | White cell enzymes | |
| Very long chain fatty acids | | | |

U&Es Urea and Electrolytes, FBC Full Blood Count, ESR Erythrocyte Sedimentation Rate, CRP C- Reactive Protein, y-GT gamma-Glutamyltransferase, TFT Thyroid Function Test, CXR Chest X-ray, αFP alpha-Fetoprotein, GAD Glutamic Acid Decarboxylase, VGCC Voltage-gated Calcium Channel, CT Computerised Tomography, FRDA Friedreich’s Ataxia, SCA Spinocerebellar Ataxia, FXTAS Fragile X Tremor-Ataxia Syndrome, CSF Cerebrospinal Fluid, OCT Optical coherence tomography, NGS Next Generation Sequencing, PET Positron Emission Tomography

efficient diagnosis and management. Important considerations in the history include the speed of symptom evolution, age at onset and family history. Patients with ataxia will typically report incoordination and unsteadiness, clumsiness, and slurred speech, and clinical signs include gait ataxia, nystagmus, hyper-hypometropic saccades and jerky pursuit when eye movements are assessed, slurred speech, intention tremor, dysmetria (or ‘past-pointing’), and dysdiadochokinesis. Diagnostic investigations are numerous and range from simple blood tests to next generation sequencing (NGS) panels, nerve conduction studies, lumbar puncture, and neuroimaging. Detailed information on tests that can be completed in primary and secondary care are shown in Table 2.

Rating scales to document the degree of impairment associated with ataxia are available, both generic (e.g. Scale for the Assessment and Rating of Ataxia (SARA), International Cooperative Ataxia Rating Scale (ICARS)) and specific for individuals forms of ataxia (e.g. Friedreich’s Ataxia Rating Scale (FARS)). Monitoring of ataxic patients’ impairments with one or more of these scales facilitates the objective recording of progression with time and enables the unbiased appraisal of interventions that are carried out. These measurements are frequently used in clinical trials of disease-modifying therapies, and in time are likely to become mandatory when such therapies are utilised in daily clinical practice (to monitor objectively the impact of such therapies on individual patients).

Table 3 summarises the main recommendations in this section.

Medical interventions
As indicated earlier, many of the interventions to ameliorate the accompanying (usually neurological) complications
in patients with ataxia are extrapolated from other conditions. The principles governing the management of spasticity and bladder symptoms could, for example, be equally well apply to patients with multiple sclerosis. In Table 4, key recommendations pertaining to the management of symptoms manifesting in ataxic patients are presented. The recommendations also cover some specific hereditary causes of ataxia, such as Episodic Ataxia type 2- where symptomatic therapies have the capacity to reduce the severity of, if not abort, bouts of ataxia.

To view the full content of the Medical intervention section, please see (https://www.ataxia.org.uk/Pages/News/Category/medical-interventions).

**Treatable ataxias**

A small number of conditions presenting with ataxia are amenable to treatment, so diagnosing these is of great importance. Table 5 lists the treatable ataxias in adults and children, and recommendations for their diagnosis and treatment. Table 6 lists recommendations for the treatment of ataxias diagnosed specifically in childhood.

**Allied health professional interventions**

Interventions by allied health professionals play a crucial role in the management of people with progressive ataxias. Additional file 1: Table S2 in the supplementary data highlights the key recommendations in the fields of physiotherapy, speech and language therapy and occupational therapy, and more detailed recommendations are available at https://www.ataxia.org.uk/Pages/News/Category/allied-health-professional-interventions. This section of the guidelines is especially valuable when referrals are made outside of specialist ataxia centres and their multidisciplinary teams, when it is recommended that on-going, “maintenance” therapy is carried out by community teams.

**Palliative care**

Palliative care is an important element of the holistic care of individuals living with incurable conditions and their families, and aims to prevent and relieve suffering by means of the early identification, comprehensive assessment and treatment of pain and other complications (encompassing the physical, psychosocial and spiritual domains) [11]. Where appropriate, palliative care also includes end-of-life planning and care. In the absence of available literature on palliative and end-of-life care in the ataxias specifically, these recommendations are derived in part from evidence of these interventions in other progressive neurodegenerative conditions [12]. The main recommendations are summarised in Additional file 1: Table S3 in the supplementary data, and available in more detail at https://www.ataxia.org.uk/palliative-care.

**Conclusions and further research**

When summarising the grades of evidence available for the recommendations highlighted in this paper, the large majority are of “Good Practice Point” standard and as such are based on clinical experience and anecdotal evidence. It is disappointing that more research has not been undertaken to support the evidence base of these interventions in clinical practice. An example is the many promising pilot studies in Physiotherapy, which have not been taken forward to larger randomised controlled trials (RCTs). Similarly, there are numerous pharmacological therapies that are being explored in
Table 4: Symptomatic treatments

4.1 Spasticity

Recommendation

Careful assessment by a neurologist, with advice from a physiotherapist, is required to decide on the type of treatment of spasticity.

Consider physiotherapy first to treat spasticity, and if that does not provide complete benefit use pharmacological treatment. Surgery should be considered in cases where physiotherapy and pharmacological treatments have not worked.

For pharmacological treatment of generalised spasticity consider using the following oral medications (usually in this order due to the profile of side effects and better tolerability): baclofen, tizanidine, gabapentin, clonazepam, dantrolene sodium or diazepam.

To treat focal spasticity refer to a specialised clinic for treatment with intramuscular botulinum toxin injections, followed by physiotherapy.

4.2 Tremor

Recommendation

Patients with ataxia who have tremors should be offered pharmacological treatment using Propranolol, Primidone, Propranolol and Primidone in combination, Topiramate, Clonazepam and Gabapentin (in this order).

In patients where tremor is extremely debilitating and not responsive to medication a referral to a centre specialising in functional neurosurgery should be considered.

4.3 Dystonia

Recommendation

Focal dystonia should be treated with botulinum toxin injections.

Generalised dystonia should be treated with oral medications, followed by surgery if this is not effective.

Patients with dystonic tremor should be offered physiotherapy and oral medications followed by surgery if the former are ineffective.

4.4 Scoliosis

Recommendation

Regular surveillance of the development of scoliosis in FRDA patients (especially children) is recommended as it is important for it to be treated.

If scoliosis is detected, referral to a physiotherapist and spinal surgeon is recommended.

For mild scoliosis the patient should be kept under close observation and the spinal surgeon should consider treatment with bracing.

For severe scoliosis consider surgery to straighten the spine.

Regular follow-up by a spinal surgeon is recommended after an operation on the spine.

4.5 Pain

Recommendation

Treat pain with physiotherapy and/or pharmacological treatments.

Consider use of the following drugs to treat neuropathic pain: Amitriptyline, Nortriptyline, Carbamazepine, Pregabalin, Gabapentin and Duloxetine.

Table 4: Symptomatic treatments (Continued)

4.6 Cardiac involvement in FRDA

Recommendation

When FRDA is diagnosed a referral to a cardiologist is recommended for the early diagnosis of cardiac problems and the management of cardiac complications, where required.

Regular screening by a cardiologist is recommended in FRDA patients; once every two years before any cardiac disease is documented, and at least annually after manifesting features of asymptomatic cardiac disease.

Transthoracic Echocardiography and ECG should be used for the diagnosis and monitoring of the myocardial changes.

Holter monitoring should be undertaken to detect silent cardiac arrhythmias or the association of symptoms (such as palpitations, shortness of breath) with the underlying rhythm.

A cardiologist should consider pharmacological treatment (including the use of anticoagulants), and in some cases the implantation of pacing devices, in collaboration with the neurologist.

4.7 Bladder problems - lower urinary tract dysfunction

Recommendation

In primary care, test for urinary tract infection and measure post-void residual (to exclude common causes of urgency and frequency). If these are normal, check for other common causes such as prostate enlargement.

Advice on pelvic floor exercises should be given as it may be helpful especially when symptoms are mild.

Most individuals with overactive bladder symptoms will require antimuscarinic medications (such as tolterodine, oxybutynin, propiverine and solifenacin).

In patients with cardiac complications and/or cognitive problems caution is advised when using antimuscarinic medications.

In patients with cognitive problems, more selectively-acting antimuscarinic medications, such as tropisulm chloride or darifenacin should be considered.

In some instances, referral to an urologist is recommended eg: in cases of haematuria or suspicion of concomitant urological condition.

4.8 Gastroenterological problems

Recommendation

Suggest changes in lifestyle (eg: diet, fluid and mobility assistance) for patients with constipation, followed by the use of laxatives or suppositories.

Consider referral for specialist assessment if patients have urgency and faecal incontinence.

4.9 Sexual dysfunction

Recommendation

GPP

GPP

GPP

GPP

GPP

GPP

GPP

GPP

GPP

GPP

GPP

GPP

GPP

GPP

GPP

GPP
Table 4 Symptomatic treatments (Continued)

| Table 4 Symptomatic treatments (Continued) |
|-------------------------------------------|
| Consider discussing sexual function with male patients due to the potential for erectile dysfunction. |
| Treat erectile dysfunction where appropriate with phosphodiesterase-5 inhibitors. Treatment decisions should balance the needs of the person and the potential side effect of medications e.g., hypotension. |
| If patients have cardiac pathologies caution should be exercised when considering medication, and consultation with a cardiologist is recommended. |
| 4.10 Swallowing and dysphagia |
| **Recommendation** |
| Grade |
| If patients show symptoms of dysphagia a referral to a speech and language therapist should be made (see Additional file 1: Table S2). |
| If there is unintentional weight loss due to dysphagia consider the use of nutritional supplements and refer to a dietician. |
| If calorie intake cannot be maintained despite supplements, discuss the possibility of a percutaneous gastrostomy (PEG) to provide secure feeding. |
| 4.11 Sialorrhoea (excessive salivation) |
| **Recommendation** |
| Grade |
| Sialorrhoea is normally associated with dysphagia, thus a referral to a speech and language therapist is recommended for assessment of swallow. |
| Treat sialorrhoea and thick secretions according to Bavikatte et al. 2012 [9] (and the full guidelines). |
| 4.12 Audiology and hearing |
| **Recommendation** |
| Grade |
| If a patient is experiencing hearing problems refer to Audiology services for a battery of hearing tests. |
| A hearing aid trial should be considered although it is often not suitable for this patient population. |
| A trial with an FM hearing device is recommended in cases of ataxia with Auditory Neuropathy Spectrum Disorder (ANSD). |
| Refer to hearing therapist or speech and language therapist for guidance on communication tactics. |
| For those who do not achieve any benefit from hearing aids, consider a referral to a cochlear implant centre. |
| In specific cases (e.g. ANSD) a referral to a neuro-otologist should be considered. |
| 4.13 Eye symptoms |
| **Recommendation** |
| Grade |
| A referral to a neuro-ophthalmologist is recommended if ataxia patients have any eye symptoms. |
| If disabling nystagmus or oscillopsia is present treatment is recommended, often with either gabapentin or baclofen. |
| Refer to an optometrist or neuro-ophthalmologist for restoration of single vision with prisms in cases of diplopia. |
| Patients with visual impairment should be offered low vision aids and the possibility of having their visual disability registered. |
| 4.14 Cognition |
| **Recommendation** |
| Grade |

pilot trials that need further investigation in larger, appropriately controlled studies.

In an era of limited health funding, the absence of evidence (through lack of trials rather than trials failing to prove efficacy) may be used to argue that these interventions should not be made available to ataxic patients, through publicly funded healthcare providers, such as the National Health Service in the UK. The need for further research is thus of paramount importance.

It is also of interest to note the limitations of the grading system adopted in the guidelines. There are some recommendations that do not lend themselves to this methodology. As such, these have been graded as Good Practice Pointers (GPP), as the absence of robust evidence from RCTs did not enable their categorisation at a higher grade. An example of this is the recommendation that genetic
tests are undertaken in accredited laboratories. Although the intention of this recommendation is for it to be strongly endorsed (as is self-evident), it may appear weak as it is graded “GPP”. In instances such as this, the recommendations given do not lend themselves naturally to this method of grading. Nevertheless, this was only true for a minority of recommendations made and generally limited to the section related to diagnosis and to some recommendations on referrals to specialists.

Despite advances in diagnostic testing, many patients with ataxia are still not given a specific diagnosis of the underlying cause of their ataxias. The availability of gene panels, and increasingly exome and whole genome sequencing, may offer greater opportunities for the accurate (genetic) characterisation of ataxic subjects and families. Whilst novel genes responsible for causing ataxia might emerge, Next Generation Sequencing also poses challenges, in deciphering the true role of genetic/genomic variants, and these technological advances need to be coupled with expert bioinformatics. The determination of the pathogenicity of “variants of unknown significance” (VUS) can be time-consuming and expensive. This has engendered an interest in “deep phenotyping”- where novel biomarkers and functional assays are utilised to assist the interpretation of genetic tests. The use of Optical Coherence Tomography (OCT) in supporting the diagnosis of Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay is a recent illustrative example [51]. This type of integrative studies is likely to prove critical in deciphering the output from NGS (including VUS) over the next decade.

The production of this third edition of the guidelines has identified persisting gaps in the management of patients with ataxia. There is an urgent and pressing need to develop agents that have a disease-modifying effect in the ataxias, a need which is shared by almost all neurodegenerative disorders. This may partly reflect the level of understanding and complexity of the biological processes underpinning these disorders, and contrasts with the promising interventions now in common use in

### Table 5 Treatable ataxias

| 5.1 Gluten ataxia | Recommendation | Grade |
|------------------|----------------|-------|
| It is recommended that patients with idiopathic cerebellar ataxia are tested for gluten sensitivity. | GPP | |
| Consider testing for antibodies against TG6 (when possible) as a more sensitive test for gluten ataxia. | C [32, 33] | |
| Ataxia patients with or without enteropathy who have serological evidence of gluten sensitivity should be advised to start a gluten-free diet without delay. | C [34] | |
| Patients who are starting a gluten-free diet should be advised about strict adherence and given dietetic advice. | GPP | |
| Close monitoring is recommended with six-monthly testing to ensure for elimination of antigliadin antibodies. | GPP | |

| 5.2 Ataxia with vitamin E deficiency | Recommendation | Grade |
|-------------------------------------|----------------|-------|
| Patients diagnosed with ataxia with vitamin E deficiency or abetalipoproteinemia should be treated with vitamin E supplements. | C [35, 36] | |

| 5.3 Ataxia with vitamin B12 deficiency | Recommendation | Grade |
|---------------------------------------|----------------|-------|
| Patients diagnosed with ataxia and Vitamin B12 deficiency should be treated with Vitamin B12. | GPP | |

| 5.4 Ataxia with CoQ10 (ubiquinone) deficiency | Recommendation | Grade |
|-----------------------------------------------|----------------|-------|
| Patients diagnosed with ataxia with CoQ10 deficiency should be treated with CoQ10 supplements. | D [37–39] | |
| Consider treatment of patients diagnosed with AOA1 with CoQ10 supplementation. | D [40, 41] | |

| 5.5 Cerebrotendinous xanthomatosis | Recommendation | Grade |
|-----------------------------------|----------------|-------|
| Prompt diagnosis of cerebrotendinous xanthomatosis is advised in order to initiate treatment. | GPP | |
| If cerebrotendinous xanthomatosis is diagnosed treatment with chenodeoxycholic acid is recommended. | B [42, 43] | |

| 5.6 Niemann-Pick type C (NPC) | Recommendation | Grade |
|--------------------------------|----------------|-------|
| If NPC is suspected based on clinical investigations, perform diagnostic tests described above. Early diagnosis is important as it is a treatable condition. | GPP | |
| If NPC is diagnosed refer promptly to a Specialist Centre for treatment and management. | GPP | |
| Treatment with Miglustat is recommended in both adult and paediatric cases and is available in Specialist Centres. | B [44–48] | |
neuroinflammatory disorders such as Multiple Sclerosis. In the more common ataxias, such as FRDA and some SCAs, much research has focused on the identification of therapeutic targets and indeed several treatment trials have taken place. Furthermore, databases have been created and natural history data are being collected by networks of researchers worldwide, and this effort is proving useful in the design and implementation of trials [13, 14]. Indeed, as a result of these developments, and the financial incentives being provided for the study of rare diseases generally, pharmaceutical and biotech companies are increasingly engaging in ataxia research and running trials often in collaboration with academic centres and patient groups, such as Ataxia UK. Given the potential advantages of speedy development, drug repurposing approaches are also being explored by ataxia researchers worldwide.

In addition to disease-modifying treatments, there are specific symptoms experienced by patients with ataxia (such as balance and coordination problems, tremor and fatigue) for which effective therapies are also lacking yet can cause significant disability. Ataxia UK has independently surveyed the opinions of 426 people with progressive ataxia, to identify what they perceived to be their most pressing medical needs. Interestingly, impairments in balance, coordination and speech were highlighted as the symptoms with greatest impact, as well as fatigue. The production of these guidelines has revealed considerable overlap between what are seen to be areas requiring further research by professionals, and symptoms requiring most amelioration identified by patients. More research is thus needed to identify novel therapies and interventions to influence these symptoms, and critically to evaluate their effectiveness.

In creating this comprehensive guidance, our aim has been to provide a useful tool for HCPs looking after patients with progressive ataxia. Any comments on the recommendations are welcomed by the Guidelines Development Group, in order to refine and improve these recommendations in future editions.

Additional file

Table 6 Treatable causes in children

| 6.1 Glucose transporter 1 deficiency |
| Recommendation |
| If Glut-1 DS is diagnosed treat with a ketogenic diet. |

| 6.2 Hypobetalipoproteinemia |
| Recommendations |
| Consider management of the moderate form of hypobetalipoproteinemia by reducing the proportion of fat in the patient’s diet and vitamin E supplementation. |

| 6.3 Hartnup disease |
| Recommendation |
| Consider treating Hartnup disease with nicotinamide or tryptophan-rich diet, and advise patients on a high protein diet, sunlight protection and avoidance of photosensitizing drugs. |

| 6.4 Biotinidase deficiency |
| Recommendation |
| Treat patients diagnosed with biotinidase deficiency with biotin. |

| 6.5 Pyruvate deficiency |
| Recommendation |
| Consider treatment with thiamine, carnitine or lipoic acid and advising on a ketogenic diet. |

| 6.6 Structural disorders |
| Recommendation |
| If ataxia is due to structural causes a referral for neurosurgical treatment may be recommended. |

Acknowledgements

We would like to thank the following specialist contributors listed alphabetically; for the full list of specialist contributors to the guidelines and their affiliations, see Additional file 1: Table S1: Claire Bates, Peter Baxter, Harriet Bonney, Fion Bremner, Lisa Bunn, Maria Carrillo Perez-Torne, Mark Chung, Lisa Cipolotti, Kate Duberley, John Ealing, Anton Emmanuel, Marios Hadjivassiliou, NS Harshavardhana, Kate Hayward, Christian Hendriksz, Joshua Hersheson, Rita Horvath, Joanne Hurford, Fatima Jaffer, Cherry Kilbride, Anja Lowit, Jonathan Marsden, Andrea Nemeth, Hilali Noordeen, Jalesh Panicker, Antonios Pantazis, Michael H Parkinson, Liz Redmond and Kai Uus. In addition, we are grateful to Adenike Deanne-Pratt, previously Ataxia UK’s Communications Officer, for her earlier contribution on the Guideline Development Group.
Funding
Not applicable.

Availability of data and materials
Not applicable.

Authors’ contributions
RDS, JG, AC, HB, JV, BH, PG contributed to the preparation of the manuscript, and all reviewed the final draft prior to submission. All authors read and approved the final manuscript.

Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Department of Neurology, Essex Centre for Neurological Sciences, Queen’s Hospital, Romford RM7 0JA, UK. 2Ataxia UK, 12 Broadbent Close, London N6 5AW, UK. 3Ataxia Centre, Department of Molecular Neurosciences, UCL Queen Square Institute of Neurology, Queen Square, London WC1N 3BG, UK.

Received: 16 September 2018 Accepted: 29 January 2019
Published online: 20 February 2019

References
1. Wardle M, Robertson N. Progressive late-onset cerebellar ataxia. Adv Clin Neurosci Rehabil. 2007;7:6–12.
2. Musselman KE, et al. Prevalence of ataxia in children: a systematic review. Neurol. 2014;82:80–9.
3. Cossee M, Schmitt M, Campuzano V, Reutenaar L, Moutou C, Mandel JL, Koenig M. Evolution of the Friedreich’s ataxia trinucleotide repeat expansion: founder effect and premutations. Proc Natl Acad Sci U S A. 1997;94(14):7452–7.
4. Daker-White G, Ealing J, Greenfield J, Kingston J, Sanders C, Payne K. Trouble with ataxia: a longitudinal qualitative study of the diagnosis and medical management of a group of rare, progressive neurological conditions. SAGE Open Med. 2013;1:205031213305560.
5. http://www.atsociety.org.uk/data/files/WilliamAT_Clinical_Guidance_Document_Final.pdf.
6. Qaseem A, et al. Guidelines international network: toward international standards for clinical practice guidelines. Ann Intern Med. 2012;156:525–31.
7. Hillier S, Grimmer-Somers K, Merlin L, Middleton P, Salisbury J, Tooth K, Weston A. FORNI: an Australian method for formulating and grading recommendations in evidence-based clinical guidelines. BMC Med Res Methodol. 2011;11:23.
8. National Health and Medical Research Council, A. G. In: NHMRC additional levels of evidence and grades for recommendations for developers of guidelines: 2009.
9. Bavikatte G, Lin Sr P, Hassoon A. Management of Drooling of saliva. BJMP. 2012;5(11):S07.
10. Depression in adults with a chronic physical health problem: recognition and management. Clinical Guideline 91. National Institute of Clinical Excellence 2009 (nice.org.uk/guidance/cg91).
11. WHO Definition of Palliative Care. World Health Organisation (http://www.who.int/cancer/palliative/definition/en/).
12. Saleem T, Leigh N, Higginson I. Symptom prevalence among people affected by advanced and progressive neurological conditions - a systematic review. J Palliat Care. 2007;23:291–9.
13. Reetz K, et al. Biological and clinical characteristics of the European Friedreich’s Ataxia consortium for translational studies (EFACTS) cohort: a cross-sectional analysis of baseline data. Lancet Neurol. 2015;14:174–82.
14. Jacobi H, et al. Long-term disease progression in spinocerebellar ataxia types 1, 2, 3, and 6: a longitudinal cohort study. Lancet Neurol. 2015;14:1101–8.
15. Pickel W, et al. Chronic thalamic stimulation in a patient with spinocerebellar ataxia type 2. Mov Disord. 2003;18(2):222–5.
16. Blomstedt P, et al. Deep brain stimulation of the posterior subthalamic area in the treatment of tremor. Acta Neurochir. 2009;151:31–6.
17. Mannus A, et al. Deep brain stimulation for the treatment of tremor and Ataxia associated with Abetalipoproteinemia. Tremor Other Hyperkinetic Mov. 2012;2.http://tremorjournal.org/article/view/45.
18. Hageman RJ, et al. Case series: deep brain stimulation in patients with FXDAS. Brain Disorders Ther. 2012;1(2). https://doi.org/10.4172/2168-975X.1000104.
19. Cady RB, et al. Incidence, natural history & treatment of scoliosis in Friedreich’s ataxia. J Ped Orthop. 1984;6(6):673–6.
20. Daher YH, et al. Spinal deformity in patients with Friedreich’s ataxia: a review of 19 patients. J Ped Orthop. 1985;5(5):533–7.
21. Labelle H, et al. Natural history of scoliosis in Friedreich’s ataxia. J Bone Joint Surg (Am). 1986;68(4):664–72.
22. Milbrandt TA, et al. Friedreich’s ataxia & scoliosis: the experience at two institutions. J Ped Orthop. 2008;28(2):234–8.
23. Tsirikos AI, Smith G. Scoliosis in patients with Friedreich’s ataxia. J Bone Joint Surg (Br). 2012;94(5):684–9.
24. Rance G, et al. Auditory processing deficits in children with Friedreich ataxia. J Child Neurol. 2012;27(9):1197–203.
25. Rance G, et al. Successful treatment of auditory perceptual disorder in individuals with Friedreich ataxia. Neuroscience. 2010;17(12):552–5.
26. Shallkop JK, et al. Cochlear implants in five cases of auditory neuropathy: postoperative findings and progress. Laryngoscope. 2011;111(4 Pt 1):555–62.
27. Bandini F, et al. Gabapentin but not vigabatrin is effective in the treatment of acquired nystagmus in multiple sclerosis: how is the GABAergic hypothesis? J Neurol Neurosurg Psychiatry. 2001;71:107–10.
28. Averbuch-Heller L, et al. A double-blind controlled study of gabapentin and baclofen as treatment or acquired nystagmus. Ann Neurol. 1997;41:818–25.
29. Snupp M, et al. Treatment of downbeat nystagmus with 3,4-diaminopyridine: a placebo-controlled study. Neurology. 2003;61:165–70.
30. Ciaccarelli I, et al. Evaluation of neuropsychological functions in patients with Friedreich ataxia before and after cognitive therapy. Funct Neurol. 2010;25:81–5.
31. Snupp M, et al. A randomized trial of 4-aminopyridine in EA2 and related familial episodic ataxias. Neurology. 2011;77:269–75.
32. Hadjivassiliou M, et al. Autoantibodies in gluten ataxia recognise a novel neuronal transglutaminase. Ann Neurol. 2008;64:332–43.
33. Hadjivassiliou M, et al. Transglutaminase 6 antibodies in the diagnosis of gluten ataxia. Neurology. 2013;80:1740–5.
34. Hadjivassiliou M, et al. Dietary treatment of gluten ataxia. J Neurol Neurosurg Psychiatry. 2003;74(9):1221–4.
35. Schuette M. Ataxia with vitamin E deficiency. GeneReviews. 2013. https://www.ncbi.nlm.nih.gov/books/NBK1241/.
36. Baumgartner MR. Vitamin-responsive disorders: cobalamin, folate, biotin, vitamins B1 and E. Handb Clin Neurol. 2013;113:799–810.
37. Rahman S, et al. 176th ENMC international workshop: diagnosis and treatment of coenzyme Q10 deficiency. Neuromuscular Disord. 2012;22(1):76–86.
38. Emmanuele V, et al. Heterogeneity to coenzyme Q10 deficiency: patient study and literature review. Arch Neurol. 2012;69:987–3.
39. Horvath R. Update on clinical aspects and treatment of selected vitamin-responsive disorders II (riboflavin and CoQ10). J Inherit Metab Dis. 2012;35:679–87.
40. Balreira A, et al. ANO10 mutations cause ataxia and coenzyme Q10 deficiency. J Neurol. 2014;261:2192–8.
41. Quinzii C, et al. Coenzyme Q deficiency and cerebellar ataxia associated with an apratamin mutation. Neurology. 2005;64(5):539–41.
42. Federico A, et al. Cerebrotendinous Xanthomatosis. Gene Rev. 2011. https://www.ncbi.nlm.nih.gov/pubmed/20301583.
43. Rafiq M, et al. Neurological rarity not to be missed: cerebrotendinous xantomatosis. Pract Neurol. 2011;11:296–300.
44. Patterson MC, et al. Stable or improved neurological manifestations during miglustat therapy in patients from the international disease registry for Niemann-Pick disease type C: an observational cohort study. Orphanet J Rare Dis. 2015;10:655.
45. Wraith JE, et al. Miglustat in adult and juvenile patients with Niemann–pick disease type C: long-term data from a clinical trial. Mol Genet Metab. 2010; 99:351–7.
46. Patterson MC, et al. Long-term Miglustat therapy in children with Niemann-pick disease type C. J Child Neurol. 2010;25:300–5.
47. Pineda M, et al. Miglustat in patients with Niemann-pick disease type C (NP-C): a multicenter observational retrospective cohort study. Mol Genet Metab. 2009;98:243–9.
48. Patterson MC, et al. Miglustat for treatment of Niemann-pick C disease: a randomised controlled study. Lancet Neurol. 2007;6:765–72.
49. Leen WG, et al. Glucose transporter-1 deficiency syndrome: the expanding clinical and genetic spectrum of a treatable disorder. Brain J Neurol. 2010; 133:655–70.
50. Wang D, et al. Glut-1 deficiency syndrome: clinical, genetic, and therapeutic aspects. Ann Neurol. 2005;57:111–8.
51. Parkinson MH, et al. Optical coherence tomography in autosomal recessive spastic ataxia of Charlevoix-Saguenay. Brain. 2018;141(4):989–99.
52. Yorkston K. M. et al. Management of Motor Speech Disorders in children and adults. (Pro-Ed, 1999). https://trove.nla.gov.au/work/79838487?q&versionId=9203354.
53. Crowdy KA, et al. Evidence for interactive locomotor and oculomotor deficits in cerebellar patients during visually guided stepping. Exp Brain Res. 2000;135:437–54.
54. Crowdy KA, et al. Rehearsal by eye movement improves visuomotor performance in cerebellar patients. Exp. Brain Res. 2002;146:244–7.
55. Ilg W, et al. Video game–based coordinative training improves ataxia in children with degenerative ataxia. Neurology. 2012;79:2056–60.